Evaluation of Antibiotic Susceptibility and Multidrug Resistance in Clinical Isolates of Pseudomonas Aeruginosa

Abstract

Pseudomonas aeruginosa has been designated as a species of "greatest public health concern" by the World Health Organization (WHO). While P. aeruginosa seldom causes serious infections in healthy people, it is linked to a number of invasive illnesses in patients who have been hospitalized for an extended period of time. patients with ventilator-associated pneumonia, those receiving cancer chemotherapy or wide spectrum antibiotic therapy, and critically ill intubated patients (World Health Organization, 2017). The objective of the study was to identify and molecularly describe resistance genes in pseudomonas aeruginosa from body blood, pus patients. Twenty (20) samples were gathered for this investigation between December 2024 and march 2025 from tertiary care facilities in Bannu, KPK, Pakistan. Twelve (12) (60%) of the samples tested positive for pseudomonas aeruginosa. Isolated strains of P. aeruginosa showed complete resistance to Colistin (100%) whereas, the zone of inhibition for Amikacin was measured as 5.8mm, Vancomycin 5.5mm, Fluoroquinolones 5.6mm, imipenem (3.3mm) tobramycin 6.5mm, Gentamicin 6.0mm, tazobactam(6.9mm), linezolid (7.5 mm), Cafdnir (6.8mm) Although the majority of MDR p. aeruginosa resistance occurs to all classes of antibiotics, the study's goal is to determine which class of antibiotic is best for treating MDR p. aeruginosa.

Keywords: Pseudomonas aeruginosa, Multidrug-resistant (MDR), Gram-negative bacteria, Antibiotic resistance